Dysregulation of miR-150-5p and its target FoxO3a in atherosclerosis (AS). by Ping-yu Cai (12389929)

Subjects:

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

(A-C) Force versus drill depth and torque versus drill depth. by Marsel Ganeyev (21453399)

Ramified microglia in the brain parenchyma of wildtype mice and the brain parenchyma without senile plaques in APP/PS1dE9 transgenic mice under chronic hyperglycemia. by Yung-Cheng Huang (3443450)

Subjects:

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Data_Sheet_1_The Ability of an Algoclay-Based Mycotoxin Decontaminant to Decrease the Serum Levels of Zearalenone and Its Metabolites in Lactating Sows.DOCX by Xandra Benthem de Grave (11504734)

“…When the HiZEN diet was supplemented with the tested algoclay-based mycotoxin decontaminant the levels of ZEN and its metabolites were significantly decreased in the serum of sows. Although all sows were fed the same levels of DON, the serum level of de-epoxy-DON was increased only in the serum of piglets from the sows fed a diet with the non-supplemented HiZEN diet. …”

ox-LDL stimulates cytotoxicity and pyroptosis among RAW264.7. by Ping-yu Cai (12389929)

Subjects:

Automated wound healing assay showing decreased motility of IL-4 treated HCAEC. by Tom Skaria (2733439)

Mean value of ENSS and subscales. by Phu Dinh Vu (19429477)

Subjects:

Quantification of ingested proteins by females after 30 minutes of blood feeding. by Tainá Neves Ferreira (21601579)

miR-150-5p inhibition modulates pyroptosis and FoxO3a/ARC signaling in ApoE^-/- mice. by Ping-yu Cai (12389929)

Subjects:

Therapeutic effects of miR-150-5p inhibition on ox-LDL-induced pyroptosis in RAW264.7 macrophages. by Ping-yu Cai (12389929)

Subjects:

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Reduction of IL-8 is associated with a relevant decrease of GBA2 expression in CF bronchial cells. by Nicoletta Loberto (2224150)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”

Time-dependent decreases in beclin-1 (A), Atg5 (B), and SIRT1 (C) protein expression in N2a cells exposed to exogenous Aβ1–42 (10μ μM). by Hye Rin Lee (616252)

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)